1 |
Lam L, Fontaine H, Lapidus N, Dorival C, Bellet J, Larrey D, Nahon P, Diallo A, Cagnot C, Lusivika-Nzinga C, Téoulé F, Hejblum G, Bourlière M, Pol S, Carrat F; ANRS/AFEF Hepather study group. Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers. Pharmacoepidemiol Drug Saf 2023;32:486-95. [PMID: 36444965 DOI: 10.1002/pds.5576] [Reference Citation Analysis]
|
2 |
Nakagawa M, Asahina Y, Kakinuma S, Okamoto R. Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR. J Gastroenterol 2022. [PMID: 36585501 DOI: 10.1007/s00535-022-01940-1] [Reference Citation Analysis]
|
3 |
Bale BF, Doneen AL, Leimgruber PP, Vigerust DJ. The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1042729] [Reference Citation Analysis]
|
4 |
Ramadan MS, Boccia F, Moretto SM, De Gregorio F, Gagliardi M, Iossa D, Durante-Mangoni E, Zampino R. Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. J Clin Med 2022;11. [PMID: 36233646 DOI: 10.3390/jcm11195781] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
5 |
Gîrleanu I, Trifan A, Huiban L, Muzîca C, Petrea OC, Sîngeap AM, Cojocariu C, Chiriac S, Cuciureanu T, Costache II, Stanciu C. Ischemic Heart Disease and Liver Cirrhosis: Adding Insult to Injury. Life (Basel) 2022;12:1036. [PMID: 35888123 DOI: 10.3390/life12071036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
6 |
Yang W, Wang Y, Zhang P, Wang T, Li C, Tong X, Zeng X, Yin Y, Tao K, Li R, Kolaczkowska E. Hepatoprotective Role of 4-Octyl Itaconate in Concanavalin A-Induced Autoimmune Hepatitis. Mediators of Inflammation 2022;2022:1-17. [DOI: 10.1155/2022/5766434] [Reference Citation Analysis]
|